Autism treatment in homeopathy - Tv9 Autism treatment in homeopathy For more content go to http://www.freetv9.com Follow us on facebook at http Follow us on twitter at twitter.comFrom:tv9teluguViews:0 0ratingsTime:24:49More inNews Politics Read more here: Autism treatment in homeopathy - Tv9 - Video … Continue reading →

Washington, November 7 (ANI): Children with autism spectrum disorders (ASD), who are given early treatment, made significant improvements in behaviour, communication, and most strikingly, brain function, a new study by Yale School of Medicine researchers has found. The results suggest that brain systems supporting social perception respond well to an early intervention behavioural program called pivotal response treatment. This treatment includes parent training, and employs play in its methods. ASDs are complex neurobiological disorders that inhibit a person's ability to communicate and develop social relationships, and are often accompanied by behavioural challenges. Until recently, autism diagnosis typically did not occur until a child was about three to five-years-old, and treatment programs were geared for this older age group. Yale Child Study Center researchers Fred Volkmar, M.D., Kevin A. Pelphrey, and their colleagues are diagnosing children as young as age one. Pivotal response treatment, developed at the University of California-Santa Barbara, combines developmental aspects of learning and development, and is easy to implement in children younger than age two. In the current study, the team used functional magnetic resonance imageing - for the first time - to measure changes in brain activity after two five-year-olds with ASD received pivotal response treatment. … Continue reading →

ScienceDaily (Nov. 6, 2012) When given early treatment, children with autism spectrum disorders (ASD) made significant improvements in behavior, communication, and most strikingly, brain function, Yale School of Medicine researchers report in a new study. The study was published in the current issue of the Journal of Autism and Developmental Disorders by Yale Child Study Center researchers Dr. Fred Volkmar, Kevin A. Pelphrey, and their colleagues. The results suggest that brain systems supporting social perception respond well to an early intervention behavioral program called pivotal response treatment. This treatment includes parent training, and employs play in its methods. ASDs are complex neurobiological disorders that inhibit a person's ability to communicate and develop social relationships, and are often accompanied by behavioral challenges. Until recently, autism diagnosis typically did not occur until a child was about three- to five-years-old, and treatment programs were geared for this older age group. Today, Volkmar and his team are diagnosing children as young as age one. Pivotal response treatment, developed at the University of California-Santa Barbara, combines developmental aspects of learning and development, and is easy to implement in children younger than age two. In the current study, the team used functional magnetic resonance imaging -- … Continue reading →

Philadelphia, PA (PRWEB) November 07, 2012 Beware of the dialysis danger zone! A popular dialysis treatment has been found to be responsible for an increased risk of sudden death from stroke and cardiac arrest. Med Recall News, the leading free Internet source on defective prescription medication and medical devices, has issued an official consumer alert today and posted free information about the dialysis treatment risk on its website. The United States Food and Drug Administration actually issued the most serious class one recall alert for a very common dialysis treatment, said Jesse Levine with MedRecall News. It caused so many health problems that they actually required the treatment to be pulled from the market. The common dialysis medication GranuFlo was found to increase bicarbonate levels in the blood, causing a condition called alkalosis. According to the FDA, alkalosis is responsible for the advanced risk of cardiac problems for users of the popular dialysis drug. In 2011, Fresenius Medical Care (FMC) issued an internal notice to its company-owned clinics, warning of the risks and side effects of GranuFlo. However; they failed to issue warnings to thousands of physicians and clinics not owned by FMC who continued to use their product. Dialysis … Continue reading →

ScienceDaily (Nov. 5, 2012) Home blood pressure monitoring may help patients with hypertension and stroke but did not improve blood pressure control for patients who had normal blood pressure at the start or those with disabilities, according to a randomized controlled trial published in CMAJ (Canadian Medical Association Journal). "Overall, home monitoring did not improve blood pressure control in an unselected group of patients with hypertension and a history of stroke. However, it was associated with more changes in antihypertensive treatment during the trial, which suggested more active management in the intervention group," writes Sally Kerry, Centre for Primary Care and Public Health, Queen Mary, University of London, UK, with coauthors. Good blood pressure control can significantly reduce the risk of recurrent stroke in the estimated 15 million people who have strokes each year worldwide. Studies show that home monitoring is associated with lower blood pressure. The study involved 381 participants aged 30 (mean 72) years from three stroke units in London, UK, who were assigned to home monitoring or to a control group of usual care. Participants in the monitoring group were given a blood pressure monitor, brief training and telephone support from a nurse. The trial, including follow … Continue reading →

BURLINGTON, Mass.--(BUSINESS WIRE)-- Decision Resources, one of the worlds leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in light of repeated clinical trial failures of investigational treatments, neurologists remain skeptical about the launch potential of pharmacotherapies in clinical-stage development for the acute or post-acute treatment of ischemic stroke. As a result, Decision Resources expects that the market for ischemic stroke therapies will continue to be a graveyard for new product development in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. According to the Pharmacor advisory service entitled Acute Ischemic Stroke, interviewed neurologists continue to express uncertainty about the probability of success for Lundbecks thrombolytic desmoteplasecurrently the only novel drug in Phase III developmentin its redesigned pivotal clinical trial program. Although Decision Resources does not currently forecast approval of desmoteplase, its approval for use within three-to-nine hours post-stroke onset could represent one of the most important therapeutic achievements in stroke in more than a decade, while expanding the proportion of ischemic stroke patients with access to acute therapy. The findings also reveal that most interviewed experts convey limited optimism that neuroprotectants will prove effective in the treatment of ischemic stroke, given countless failures … Continue reading →